Literature DB >> 7083631

Complement activation in chronic liver disease.

L E Munoz, D De Villiers, D Markham, K Whaley, H C Thomas.   

Abstract

Patients with HBsAg positive chronic active liver disease (CALD) and primary biliary cirrhosis (PBC) exhibit increased C3d concentrations and changes in the serum concentrations of the complement components consistent with activation of the classical and alternative pathways. In these patients the concentrations of the regulatory proteins, C3b inactivator (C3bINA) and beta IH globulin, are normal. Patients with HBsAg negative CALD and alcohol induced liver disease (ALD) exhibit no evidence of an increased level of complement system activation. In these patients diminished serum concentrations of complement components appear to be related to diminished hepatic synthetic function. C4 synthesis may be specifically reduced in autoimmune chronic active liver disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083631      PMCID: PMC1536431     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator.

Authors:  K Whaley; S Ruddy
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

3.  Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.

Authors:  B J Potter; E Elias; E A Jones
Journal:  J Lab Clin Med       Date:  1976-09

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

5.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

6.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

7.  Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system.

Authors:  P Teisberg; E Gjone
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

8.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

9.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

10.  Properdin factor D. II. Activation to D by properdin.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Lupus-related hepatitis: complication of lupus or autoimmune association? Case report and review of the literature.

Authors:  Roop Kaw; Carmen Gota; Ana Bennett; David Barnes; Leonard Calabrese
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

2.  Complement factor H-deficient mice develop spontaneous hepatic tumors.

Authors:  Jennifer Laskowski; Brandon Renner; Matthew C Pickering; Natalie J Serkova; Peter M Smith-Jones; Eric T Clambey; Raphael A Nemenoff; Joshua M Thurman
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

3.  Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality.

Authors:  C Homann; K Varming; K Høgåsen; T E Mollnes; N Graudal; A C Thomsen; P Garred
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 4.  Problems of bacterial infection in patients with liver disease.

Authors:  R J Wyke
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

5.  Activation of the classical complement pathway in spontaneous bacterial peritonitis.

Authors:  G Bird; G Senaldi; M Panos; N Rolando; G Alexander; D Vergani; R Williams
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

6.  Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia; Thomas B Ledue; Wendy Y Craig
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

7.  Clinical application of a new nephelometric technique to measure complement activation.

Authors:  D Vergani; L Bevis; B A Nasaruddin; G Mieli-Vergani; D E Tee
Journal:  J Clin Pathol       Date:  1983-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.